Abstract
This review article systematically and critically summarizes the current evidence regarding desipramine for treating children and adolescents with attention deficit hyperactivity disorder (ADHD).
PRISMA guideline was used for gathering the data. The databases of PubMed/Medline and Google scholar were electronically searched. This review included controlled clinical trials investigating the efficacy of desipramine for treating children and adolescents with ADHD.
The primary outcome measure was clinical improvement measured by valid and reliable objective instruments in order to assess the severity of ADHD clinical symptoms. Adverse effects were evaluated as well.
Out of 267 titles under the study, thirty three articles mentioned desipramine for treating ADHD. Two trials met the inclusion criteria. Desipramine decreases ADHD clinical symptoms. However, there are many concerns about its safety and efficacy.
In view of serious concerns about its safety and lack of enough well-controlled trials providing strong evidence about the efficacy of desipraimine, it should be prescribed for treating children with ADHD with a high precaution, and further well-controlled trials should be performed.
Keywords: Adolescents, antidepressive agents, attention deficit hyperactivity disorder, children, desipramine, therapeutics, tricyclic.
Current Drug Safety
Title:A Systematic Review of the Efficacy and Safety of Desipramine for Treating ADHD
Volume: 8 Issue: 3
Author(s): Ahmad Ghanizadeh
Affiliation:
Keywords: Adolescents, antidepressive agents, attention deficit hyperactivity disorder, children, desipramine, therapeutics, tricyclic.
Abstract: This review article systematically and critically summarizes the current evidence regarding desipramine for treating children and adolescents with attention deficit hyperactivity disorder (ADHD).
PRISMA guideline was used for gathering the data. The databases of PubMed/Medline and Google scholar were electronically searched. This review included controlled clinical trials investigating the efficacy of desipramine for treating children and adolescents with ADHD.
The primary outcome measure was clinical improvement measured by valid and reliable objective instruments in order to assess the severity of ADHD clinical symptoms. Adverse effects were evaluated as well.
Out of 267 titles under the study, thirty three articles mentioned desipramine for treating ADHD. Two trials met the inclusion criteria. Desipramine decreases ADHD clinical symptoms. However, there are many concerns about its safety and efficacy.
In view of serious concerns about its safety and lack of enough well-controlled trials providing strong evidence about the efficacy of desipraimine, it should be prescribed for treating children with ADHD with a high precaution, and further well-controlled trials should be performed.
Export Options
About this article
Cite this article as:
Ghanizadeh Ahmad, A Systematic Review of the Efficacy and Safety of Desipramine for Treating ADHD, Current Drug Safety 2013; 8 (3) . https://dx.doi.org/10.2174/15748863113089990029
DOI https://dx.doi.org/10.2174/15748863113089990029 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications
Current Cardiology Reviews Oxidative Stress and Opioids' Toxicity: An Update
Mini-Reviews in Organic Chemistry Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Transcription Factors in Heart: Promising Therapeutic Targets in Cardiac Hypertrophy
Current Cardiology Reviews Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Locked Nucleic Acid Holds Promise in the Treatment of Cancer
Current Pharmaceutical Design Bioactivity and Enzyme Inhibition Properties of Stevia rebaudiana
Current Enzyme Inhibition The Trigeminocardiac Reflex as Oxygen Conserving Reflex in Humans: Its Ischemic Tolerance Potential
Vascular Disease Prevention (Discontinued) Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes
Current Drug Delivery Subdural Pharmacotherapy for the Treatment of Intractable Focal Neocortical Epilepsy
Drug Delivery Letters SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Probiotics as an Adjunct Approach to the Prevention and Treatment of Colon Cancer: A Review
Current Nutrition & Food Science Purification and Characterization of an Anticalcifying Protein from the Seeds of Trachyspermum ammi (L.)
Protein & Peptide Letters Anderson-Fabry Disease in Children
Current Pharmaceutical Design An Overview of Recent Patents on Composition of Mucoadhesive Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling
CNS & Neurological Disorders - Drug Targets Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes
Current Drug Targets